Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The number of circulating endothelial cells and their progenitors is increased in some types of cancer, and there is evidence that aspects of these cells might correlate with clinical outcome of cancer patients treated with anti-angiogenic drugs.
Polycomb group (PcG) proteins are epigenetic gene silencers that are implicated in neoplastic development. How do PcGs regulate cellular identity, and how might these functions be relevant during tumorigenesis?
Research on microRNAs in cancer is moving apace. This Review discusses why miRNA profiling is proving to be a useful new tool for identifying tumour subtypes, and can accurately predict patient outcome. Could miRNAs be exploited to treat tumours?
Given the lack of progress in curing metastatic epithelial cancers, there is intense interest in cancer chemoprevention strategies. However, the serious side effects that have been identified in some cancer prevention trials underscore the need to re-evaluate our approach to clinical chemopreventative drug development.
Clinical trials have shown that tumours have a modest response to EGFR inhibitors when used alone. Will they prove to be more effective when combined with radiotherapy or chemotherapy or both?
Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). Can inherited genetic factors and a better understanding of the biology of CIOF be used to provide optimal counselling for these women?
As the eightieth anniversary of the first description of Fanconi anaemia approaches, Stephan Lobitz and Eunike Velleuer look back on his career as a paediatrician and his contribution to cancer research.
